Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction

A technology of methylnaltrexone and medroxymorphone, which is applied in the field of compositions for the treatment of postoperative gastrointestinal dysfunction, and can solve problems such as inconsistency and lack of statistical significance in endpoint studies

Inactive Publication Date: 2008-03-05
PROGENICS PHARMA INC
View PDF21 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A series of phase III human studies using oral doses of 6 mg and 12 mg Alvimopan produced inconsistent results that were not statistically significant for many endpoints studied

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
  • Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Example 1: Study Design

[0094]The study was a double-blind, randomized, parallel-group study designed to evaluate the safety and activity of IV (intravenous) MNTX in the treatment of patients undergoing laparotomy for partial colectomy and the duration of their postoperative ileus. Patients were randomly assigned to placebo (saline) or a fixed dose of IV MNTX 0.30 mg / kg patient body weight in 50cc 0.9% normal saline, injected into a large vein with IV piggyback (IVPB) and Infuse for 20 minutes every 6 hours until 24 hours after the patient can tolerate solid food, until the patient is discharged from the hospital, or for a maximum of 7 days. These time points for study drug discontinuation were chosen to allow analysis of the secondary efficacy endpoints of IV MNTX as well as the primary endpoint.

[0095] 65 patients were enrolled in approximately 8 study centers. This suggested sample size has approximately 80% power to test for differences between treatment gro...

Embodiment 2

[0116] Example 2: Treatment of Patient

[0117] Screening (up to 2 weeks prior to surgery) All patients meeting eligibility criteria were explained to the study and given informed consent at their preoperative visit. Obtained for all patients including vital signs, detailed medical history, laboratory tests (Chemistry panel and complete blood count (CBC) with differential and including platelets), 12-lead supine, resting ECG, and all past and Physical exam including current drug check. Females of childbearing potential had a negative urine pregnancy test at least 2 days prior to dosing.

[0118] Day of Surgery Within 24 hours of surgery, patients were randomized to MNTX 0.30 mg / kg or placebo (saline) dose.

[0119] Pre-Induction Care All patients had IV catheters inserted on arrival at the pre-induction area or operating room. After induction, all patients received 7-10 ml / kg intravenous fluid every hour.

[0120] Anesthesia Care Prior to anesthesia, patients received mi...

Embodiment 3

[0136] Example 3. Research steps

[0137] Perform the following steps for each patient, as described below:

[0138] Physical exam / vital signs (screening and end of treatment or premature termination visit)

[0139] ●Laboratory evaluation (screening and end of treatment or premature termination visit)

[0140] ●Electrocardiogram (ECG)

[0141] ●Vital signs before and after administration

[0142] ● Verbal Numeral Scale / Vomiting Assessment

[0143] ●Presence or absence of nasogastric tube (NGT) or orogastric tube (OGT)

[0144] ●Liquid to try

[0145] Regardless of bowel sounds, at each visit to the patient at 7 am, 12 pm, 5 pm, and 10 pm (±30 minutes) beginning at the first scheduled time point in the postoperative morning, a qualified study designator passed the patient Give the patient 30 cc of water (measured with an oral syringe) through the mouth until the patient can tolerate the 30 cc of fluid. Intolerance to clear fluids was prescribed as nausea and / or vomitin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to view more

Abstract

Methods and compositions for treating post-surgical gastrointestinal dysfunction are provided. Methods include administering a quaternary derivative of noroxymorphone (e.g., methylnaltrexone) to a patient after a segmental colectomy is performed on the patient.

Description

technical field [0001] The present invention relates to compositions and methods for treating postoperative gastrointestinal dysfunction. Background technique [0002] Gastrointestinal dysfunction is a temporary side effect of abdominal surgery. Postoperative gastrointestinal dysfunction is caused by impaired gastrointestinal motility and is characterized by delayed or reduced gastric emptying, partial or complete inhibition of intestinal motility (eg, partial or complete loss of peristaltic function of at least part of the bowel), oral- Slowing or complete inhibition of cecal transit, and / or reduced or absent defecation. Postoperative gastrointestinal dysfunction can cause nausea, vomiting, difficulty or intolerance to drinking liquids or ingesting solids, bloating, gastrointestinal pain, and difficulty or inability to breathe (fart) or have a bowel movement (bowel motility). [0003] Gastrointestinal dysfunction after abdominal surgery is thought to be caused in part by ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/485A61P1/10
CPCA61K31/485A61P1/10A61P41/00
Inventor 罗伯特·J·伊斯雷尔
Owner PROGENICS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap